22 March 2024
22 March 2024
In the ONWARDS clinical programme, Awiqli offered superior blood sugar reduction in type 2 diabetes patients.
The Phase III KEYLYNK-006 study evaluating a Keytruda/Lynparza combination treatment failed to meet its primary endpoints.
Clinical trials demonstrated felzartamab’s potential to improve outcomes in diseases caused by pathogenic antibodies.
Different therapeutic approaches against antibiotic-resistant bacteria were highlighted throughout day two of the ELRIG UK conference.
The company will leverage its Mirador360 engine to develop treatments for immune-mediated disease.
The merged business, with $225m in funds, will focus on advancing presbyopia treatment.
Nouscom is part of a cancer vaccine landscape that has recently jump-started following years of dormancy.
Bionomics plans to meet with the FDA following positive topline data from the Phase IIb ATTUNE trial of the post-traumatic stress disorder (PTSD) drug BNC210.
Merging industry-leading business intelligence & award-winning journalism, this is an unrivalled opportunity for engagement with B2B professionals across a network of 40+ leading media websites.
Steer your business strategy with key data and insights from our latest market research reports and company profiles. Not ready to buy? Start small by downloading a sample report first.
Give your business an edge with our leading industry insights.
